Skip to main content

Advertisement

Table 2 Survival Data

From: A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer

  Cilengitide + Gemcitabine n = 46 Gemcitabine n = 43
Number of deaths 41 37
Median survival (95% CI), days 204 (154–292) 234 (137–290)
1-year survival (95% CI) 0.15 (0.04–0.26) 0.24 (0.11–0.37)
Median PFS (95% CI), days 110 (59–154) 115 (62–178)
  1. Abbreviation: CI, confidence interval.